Trump Says Becton Dickinson to Invest $3 Billion to Expand US Medical Product Manufacturing

Home / Blog Details

user Admin_Adham
5th Oct, 2026 12:00 AM
Test

Trump Says Becton Dickinson to Invest $3 Billion to Expand US Medical Product Manufacturing

Oct 5 (Reuters) - American medical technology company Becton ⁠Dickinson has agreed to invest $3 ⁠billion to bring manufacturing ⁠of essential ‌medical products to the United States, President Donald Trump said on ‌Monday in a post ​on the ‌Truth ‌Social website.

BD will invest more than $1 ⁠billion in ‌Nebraska to ⁠ramp ​up production ‌of numerous products, including needles made with American ​steel, Trump ‌said.

Becton ‌Dickinson did not immediately ‌reply ​to a request from comment from Reuters.

(Reporting ⁠by Disha Mishra in ‌Bengaluru; Editing by ​Christian Schmollinger)

Article Key Points
  • BD to invest $3B to expand US medical product manufacturing.
  • >$1B earmarked for Nebraska production scale-up.
  • Essential medical products targeted for domestic supply chain expansion.
  • Needle production to use American steel.
  • Company response not yet provided; implementation details unclear.
Dive Deeper
How does domestic medical supply reshoring affect device shortages?
What regulatory hurdles delay US medical manufacturing expansion?
Which essential products most benefit from US production?
Dive Deeper
Commonly Asked by HCPs
Q: What are the implications of reshoring medical manufacturing for device access and costs?
A: Reshoring medical manufacturing may improve supply security and responsiveness, but it can also influence procurement costs, capacity planning, and market competition. Clinicians and health systems commonly examine whether domestic production meaningfully improves access to essential devices without creating new affordability or distribution challenges.
Read full answer
Q: How do supply chain disruptions affect availability of needles, syringes, and other disposables?
A: Supply chain disruptions can limit access to basic devices such as needles, syringes, catheters, and other disposables, affecting routine care across inpatient and outpatient settings. Common themes include inventory buffering, alternate sourcing, single-use device allocation, and the clinical impact of delayed or substituted supplies.
Read full answer
Q: What quality and regulatory standards govern domestic production of medical products?
A: Medical product manufacturing in the United States is shaped by FDA requirements, quality systems, sterility controls, traceability, and postmarket surveillance. Physicians researching this topic often look for how domestic production aligns with device safety, consistency, and compliance across high-volume essential products.
Read full answer
Q: How should hospitals reduce vulnerability to shortages of critical medical supplies?
A: Hospitals typically reduce shortage risk through diversified vendors, demand forecasting, conservation protocols, formulary review, and contingency planning for critical supplies. Research in this area often addresses which operational strategies best preserve procedure capacity and patient safety when supply chains are unstable.
Read full answer
Q: What are current U.S. manufacturing considerations for essential medical devices and supplies?
A: Domestic manufacturing of essential medical products is usually discussed in the context of supply resilience, regulatory oversight, and strategic capacity for high-use consumables. Clinicians researching this area often focus on how production location affects availability, quality control, and continuity of care during shortages or disruptions.
Read full answer
Reuters Health Information © 2026 Reuters Ltd.

Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.


Share This Article

Comments

Leave a comment

Recent Posts

Low Risk for Later Unprovoked Seizures After Acute Seizures
Kennedy Says Trump Administration Aims for Regulated Market for Peptides
Nirsevimab Prophylaxis Tied to Fewer Ear Infections

Blog categories

Shopping Cart

Loading...